Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab vs Standard of Care in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
NCT06230224Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of odronextamab in B-cell non-Hodgkin lymphoma, sponsored by Regeneron Pharmaceuticals. Started Feb 2024; status: active, not recruiting.
02
Drugs
odronextamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06230224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230224.